Psoriasis Completed Phase 1 / 2 Trials for Daclizumab (DB00111)

Also known as: Psoriasis unspecified / Psoriasis, unspecified

Indication	Status	Phase
DBCOND0013339 (Psoriasis)	Completed	1 / 2

clinicaltrials.gov Identifier	Title	Purpose	Drugs
NCT00050661	To Study the Use of Humanized CD25 in Preventing the Relapse of Psoriasis Vulgaris	Treatment	Daclizumab (DB00111)
NCT00050648	To Study the Effects of CD25 and Low Dose Cyclosporin in the Treatment of Active Psoriasis Vulgaris	Treatment	Cyclosporine (DB00091) Daclizumab (DB00111)